Sentence examples for binding experiments we identified from inspiring English sources

From rosette binding experiments we identified 7 probes whose binding was correlated in a statistically significant fashion with EGFR mutation status: Grb2, ShcA ptb), Grap2, Brk, Txk, CblB and CblA (Fig. 3A) (refer to Suppl. Table S3 for SH2 domain names and corresponding proteins).

From ChIP-exo experiments, we identified 25 reproducible binding sites for OmpR under osmotic stress (Fig. 1b and Supplementary Table 1).

With BRD4 ChIP experiments, we identified 1885 significant BRD4-binding site peaks (FDR<5%) when combining enriched peaks of our two ChIP-Seq experiments.

Using pull down experiments, we identified the HARP receptors RPTPβ/ζ, ALK and nucleolin as P111-136 binding proteins.

In an additional experiment, we identified the Cdc42 binding site on Cdc10 validating our previous results.

From this experiment, we identified the peptide, DNVYY, as the minimum sequence required for binding.

Yeast two hybrid and direct binding experiments have identified that both inner and outer COPII subunits, Sec24 and Sec13/31, bind to the central conserved domain of Sec16.

Our DNA binding experiments identified a CR3 region of the JCV 98 bp repeat that is conserved in PML (Mad) and non-PML (archetype) strains of JCV as the primary target for SF2/ASF.

In the previous experiments we could identify three lectins with opposing binding sites which are able to crosslink adjacent vesicles.

Indeed, TAL1 binding to E-box DNA motifs (CANNTG) requires heterodimerization with an E-protein and in vitro binding selection experiments have identified a TAL1/E-protein heterodimer's preferred E-box (CA GATG), which differs from the E-protein homodimers' preferred E-box (CA GGTG) (Hsu et al, 1994).

This model has been employed to perform docking and molecular dynamic simulations on WIN-55,212-2 (commonlyist commonly used in binding experiments), in order to identify the putative CB2 receptor agonist binding site, followed by molecular docking studies on a series of indol-3-yl-tetramethylcyclopropyl ketone derivatives, a novel class of potent CB2 agonists.